Compare Ginkgo Bioworks Holdings Inc (DNA) vs Herbalife Nutrition Ltd (HLF) Price & Performance

Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with negative cash flow. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting ongoing strategic initiatives despite financial challenges.

The outlook remains speculative given persistent losses and cash burn, though analyst consensus is divided. Key risks include execution on revenue growth and path to profitability. Upside depends on successful commercialization of its biotech platform and partnerships, but high volatility and fundamental weakness warrant caution for investors.

HLF trades at $12.82, up 1.34% today, with a bullish technical signal from moving averages and oscillators. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025 and Q2 2026. Revenue has been stable around $5.0B annually, with a net income margin of 4.53% in 2025. Recent news includes a $250 million share repurchase program and a planned CEO transition effective October 31, 2026.

The stock appears undervalued with a P/E of 8.22 and P/S of 0.26, supported by a 53.84% analyst buy rating and a $19.00 consensus price target. Key risks include high debt levels, with total liabilities at $3.53B, and inconsistent earnings performance. Positive cash flow trends in 2026 projections and margin expansion plans offer potential upside, but investor caution is warranted due to ongoing leadership changes and competitive pressures.